Cite
HARVARD Citation
Baldin, G. et al. (2019). Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV‐infected patients in clinical practice: results from a multicentre, observational study. HIV medicine. 20 (2), pp. 164-168. [Online].